<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955641</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-16-3197-AL-CTIL</org_study_id>
    <nct_id>NCT02955641</nct_id>
  </id_info>
  <brief_title>Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy</brief_title>
  <official_title>Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and need for prescribing
      anti-inflammatory topical drops to patients undergoing laser peripheral iridotomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary closed angle glaucoma is responsible to almost half glaucoma related blindness around
      the world. Laser peripheral iridotomy (LPI) is a common and simple treatment used for both
      treatment and prevention of acute angle closure event.

      Anti-inflammatory drops are commonly prescribed to patients undergoing LPI in order to
      prevent or reduce post-treatment discomfort. However, to date, there are no specific
      guidelines for post LPI anti-inflammatory treatment, nor sufficient clinical evidence
      regarding the efficacy of such treatment.

      In the current study, the investigators aim to evaluate the effect of topical steroids and
      non-steroidal anti-inflammatory drugs (NSAIDs) on post LPI symptoms and inflammation markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>At four days post LPI treatment</time_frame>
    <description>Using VAS pain scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms score</measure>
    <time_frame>At four days post LPI treatment</time_frame>
    <description>Using a modified questionnaire based on the ocular surface disease index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grading of cells in the anterior chamber</measure>
    <time_frame>At four days post LPI treatment</time_frame>
    <description>Assessed by counting the number of cells in the anterior chamber and applying the SUN working group grading scheme for anterior chamber cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency of LPI by visualisation</measure>
    <time_frame>up to 30 days post LPI treatment</time_frame>
    <description>Assessed on slit-lamp examination using transilumination and visualising the site of LPI treatment for the presence (patent) or obsence (closed) of transilumination defect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grading of flare in anterior chamber</measure>
    <time_frame>At four days post LPI treatment</time_frame>
    <description>Assessed by counting the number of cells in the anterior chamber and applying the SUN working group grading scheme for anterior chamber flare</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Glaucoma, Closed-Angle</condition>
  <condition>Glaucoma, Narrow-Angle</condition>
  <condition>Glaucoma, Angle-Closure</condition>
  <arm_group>
    <arm_group_label>NSAIDs-Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive Nepafenac 0.1%in the first eye, and Hydroxyethylcellulose 0.19% in the second eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-NSAIDs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive Hydroxyethylcellulose 0.19% in the first eye, and Nepafenac 0.1%in the second eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid-Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive Dexamethasone Disodium Phosphate 0.1% in the first eye, and Hydroxyethylcellulose 0.19% in the second eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive Hydroxyethylcellulose 0.19%in the first eye, and Dexamethasone Disodium Phosphate 0.1%in the second eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Disodium Phosphate 0.1%</intervention_name>
    <description>four drops a day for four days after LPI treatment</description>
    <arm_group_label>Steroid-Placebo</arm_group_label>
    <arm_group_label>Placebo-Steroids</arm_group_label>
    <other_name>Sterodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac 0.1%</intervention_name>
    <description>four drops a day for four days after LPI treatment</description>
    <arm_group_label>NSAIDs-Placebo</arm_group_label>
    <arm_group_label>Placebo-NSAIDs</arm_group_label>
    <other_name>Nevanac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyethylcellulose 0.19%</intervention_name>
    <description>four drops a day for four days after LPI treatment</description>
    <arm_group_label>NSAIDs-Placebo</arm_group_label>
    <arm_group_label>Placebo-NSAIDs</arm_group_label>
    <arm_group_label>Steroid-Placebo</arm_group_label>
    <arm_group_label>Placebo-Steroids</arm_group_label>
    <other_name>Lyteers ophthalmic solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary narrow/closed angle by gonioscopy

          -  Able to give consent

          -  Ability to attend follow-up visits

        Exclusion Criteria:

          -  Corneal disease preventing sufficient evaluation of the angle

          -  Secondary closed angle (e.g. uveitis related)

          -  Pregnant women

          -  Previous eye surgery other than laser refractive correction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Leshno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ari Leshno, MD</last_name>
    <phone>+972-3-5302874</phone>
    <email>ari.leshano@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel HaShomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Leshno</last_name>
      <email>arileshno@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Laser peripheral iridotomy</keyword>
  <keyword>topical anti-inflammatory drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

